• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Avinger Reports Third Quarter 2023 Results

    10/26/23 4:01:00 PM ET
    $AVGR
    Medical/Dental Instruments
    Health Care
    Get the next $AVGR alert in real time by email

    REDWOOD CITY, CA / ACCESSWIRE / October 26, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2023.

    Third Quarter and Recent Highlights

    • Third quarter revenue of $1.8 million, and gross margin of 21%
    • Initiated full commercial launch for Tigereye ST, Avinger's most advanced image-guided CTO-crossing device, in September
    • Commenced limited launch of the new Pantheris LV (large vessel) image-guided atherectomy device
    • Advanced development of the first-ever image-guided coronary CTO-crossing system, including successful completion of additional animal and cadaver heart studies, in preparation for IDE submission anticipated mid-2024
    • Named Phil Preuss to new position of Chief Commercial Officer in October, to lead sales force expansion and drive revenue growth initiatives
    • Released updated, best-in-class interim data from the Pantheris SV IMAGE-BTK (below-the-knee) study in key opinion leader presentation at the AMP clinical conference
    • Strengthened balance sheet through conversion of $1.9 million or 12% of outstanding debt to a new series of convertible preferred stock, and raising net proceeds of $5.1 million through the sale of common stock in the company's at-the-market (ATM) facility

    "With full commercial launch of our Tigereye ST CTO-crossing catheter and limited launch of our new Pantheris LV image-guided atherectomy system in the third quarter, exciting new clinical outcomes data for our Pantheris SV below-the-knee atherectomy device, and the outstanding performance and increased mobility of our Lightbox 3 imaging console launched last year, we have built the most advanced peripheral products portfolio in the industry," commented Jeff Soinski, Avinger's President and CEO.

    "To support the launch of our new product offerings and drive meaningful revenue growth in 2024, we are commencing an expansion of our sales team with plans to increase the size of our direct sales force by more than 25% in the fourth quarter. I am thrilled to have Phil Preuss lead these efforts in his new role as Chief Commercial Officer. Phil brings over 15 years of direct industry experience to this expanded role and has been deeply involved in the commercial launch and development of our advanced product portfolio in his prior position as Chief Marketing Officer.

    "We continue to make excellent progress on the development of our first coronary product application, including the successful completion of animal studies and cadaver heart studies in an innovative coronary test model at a leading clinical institution. We are excited about the results we are seeing as we continue to advance our lead design candidate and anticipate filing an IDE application with the FDA by mid-2024 to allow for the initiation of a clinical study following approval. Our first entry into the coronary space is designed to provide superior, simplified, and more predictable clinical outcomes while crossing chronic total occlusions in the coronary arteries, and we are excited about the prospect of extending our proprietary image-guided approach to this large and underserved market with well-established reimbursement."

    Third Quarter 2023 Financial Results

    Total revenue was $1.8 million for the third quarter of 2023, compared with $2.0 million in the second quarter of 2023 and $2.3 million in the third quarter of 2022 . The change in sales revenue primarily reflected a decrease in sales headcount, while sales productivity for existing team members remained consistent with the prior quarter. The company has hired two new clinical specialists in October as a first step in expanding our clinical support capabilities with the hiring of additional sales and clinical support personnel planned for the fourth quarter.

    Gross margin for the third quarter of 2023 was 21%, compared with 30% in the second quarter of 2023 and 35% in the third quarter of 2022. The change in gross margin primarily reflected lower manufacturing volume over fixed costs in the third quarter. Operating expenses for the third quarter of 2023 were $4.4 million, up slightly from $4.3 million in the second quarter of 2023 and down from $4.5 million in the third quarter of 2022 as the company maintains an efficient operating expense structure.

    Net loss and comprehensive loss for the third quarter of 2023 was $4.5 million, compared with $4.2 million in the second quarter of 2023 and $4.1 million in the third quarter of 2022.

    Adjusted EBITDA, as defined under non-GAAP financial measures in this press release, was a loss of $3.7 million, up slightly from a loss of $3.4 million in the second quarter of 2023 and a loss of $3.6 million in the third quarter of 2022. For more information regarding non-GAAP financial measures discussed in this press release, please see "Non-GAAP Financial Measures" below, as well as the reconciliation of non-GAAP measures to the nearest GAAP measure, provided in the tables below.

    Cash and cash equivalents totaled $8.7 million as of September 30, 2023.

    Conference Call

    Avinger will hold a conference call today, October 26, 2023, at 4:30pm ET to discuss its third quarter 2023 financial results.

    To listen to a live webcast, please visit http://www.avinger.com and select Investor Relations. To join the call by telephone, please dial +1-973-528-0011 and use passcode 782086. A webcast replay of the call will be available on Avinger's website following completion of the call at www.avinger.com.

    About Avinger, Inc.

    Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot and Tigereye ® family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

    Follow Avinger on Twitter and Facebook.

    Forward-Looking Statements

    This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our future performance, our expected hiring of additional sales and clinical support personnel, patient and physician benefits of our products , the impacts of our products on the treatment of vascular disease, our ability to successfully develop new products, including products relating to the treatment of coronary artery disease (CAD), the timing of the development of new products, the impact of products developed for the treatment of CAD on our business and results of operations, the potential success of our coronary product application, and our expectation regarding the timing relating to our goal of filing an IDE application relating to a clinical study, and the timing regarding the initiation of a clinical study. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include our dependency on a limited number of products; the resource requirements related to Pantheris, Tigereye and our Lightbox imaging console; the outcome of clinical trial results; the adoption of our products by physicians; our ability to obtain regulatory approvals for our products; as well as the other risks described in the section entitled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2023, as amended, and Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Avinger disclaims any obligation to update these forward- looking statements.

    Non-GAAP Financial Measures

    Avinger has provided in this press release financial information that has not been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The Company uses these non-GAAP financial measures internally in analyzing its financial results and believes that the use of these non-GAAP financial measures is useful to investors as an additional tool to evaluate ongoing operating results and trends and in comparing the Company's financial results with other companies in its industry, many of which present similar non-GAAP financial measures.

    The presentation of these non-GAAP financial measures should not be considered in isolation or as a substitute for comparable GAAP financial measures, and should be read only in conjunction with the Company's financial statements prepared in accordance with GAAP. A reconciliation of the Company's non-GAAP financial measures to their most directly comparable GAAP measures has been provided in the financial statement tables included in this press release, and investors are encouraged to review these reconciliations.

    Adjusted EBITDA. Avinger defines Adjusted EBITDA as net loss and comprehensive loss plus interest expense, net, plus other income, net, plus stock-based compensation expense plus certain inventory charges plus certain depreciation and amortization expense. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools. Furthermore, these non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP, and the components that Avinger excludes in its calculation of non-GAAP financial measures may differ from the components that its peer companies exclude when they report their non-GAAP results of operations. Avinger compensates for these limitations by providing specific information regarding the GAAP amounts excluded from these non-GAAP financial measures. In the future, the Company may also exclude other non-recurring expenses and other expenses that do not reflect the Company's core business operating results.

    Investor Contact:

    Matt Kreps
    Darrow Associates Investor Relations
    (214) 597-8200
    [email protected]

    Public Relations Contact:

    Phil Preuss
    Chief Commercial Officer
    Avinger, Inc.
    (650) 241-7942
    [email protected]

    Statements of Operations and Comprehensive Loss
    (in thousands, except per share amounts) (unaudited)

    For the Three Months Ended Nine Months Ended
    September 30, June 30, September 30, September 30, September 30,
    2023 2023 2022 2023 2022
    Revenues
    $1,817 $2,041 $2,252 $5,746 $6,272
    Cost of revenues
    1,429 1,436 1,462 4,117 4,301
    Gross profit
    388 605 790 1,629 1,971
    Operating expenses
    Research and development
    1,044 988 1,086 3,388 3,244
    Selling, general and administrative
    3,377 3,346 3,384 10,261 10,862
    Total operating expenses
    4,421 4,334 4,470 13,649 14,106
    Loss from operations
    (4,033) (3,729) (3,680) (12,020) (12,135)
    Interest expense, net
    (455) (445) (407) (1,292) (1,286)
    Other income (expense), net
    12 (2) - 16 (20)
    Net loss and comprehensive loss
    (4,476) (4,176) (4,087) (13,296) (13,441)
    Waiver (accretion) of preferred stock dividends
    2,436 (1,218) (1,127) - (3,381)
    Deemed dividend arising from beneficial conversion feature of convertible preferred stock
    - - - - (5,111)
    Net loss applicable to common stockholders
    $(2,040) $(5,394) $(5,214) $(13,296) $(21,933)
    Net loss per share attributable to common stockholders
    basic and diluted
    $(2.92) $(8.86) $(11.51) $(21.48) $(56.67)
    Weighted average common shares used to compute
    net loss per share, basic and diluted
    698 609 453 619 387

    Reconciliation of Adjusted EBITDA to Net Loss and Comprehensive Loss
    (in thousands) (unaudited)

    For the Three Months Ended Nine Months Ended
    September 30, June 30, September 30, September 30, September 30,
    2023 2023 2022 2023 2022
    Net loss and comprehensive loss
    $(4,476) $(4,176) $(4,087) $(13,296) $(13,441)
    Add: Interest expense, net
    455 445 407 1,292 1,286
    Add: Other income (expense), net (1)
    (12) 2 - (16) 20
    Add: Stock-based compensation
    219 239 39 703 127
    Add: Certain depreciation and amortization charges
    74 68 54 214 133
    Adjusted EBITDA
    $(3,740) $(3,422) $(3,587) $(11,103) $(11,875)

    (1) Other income(expense), net primarily represents other miscellaneous income and expenses. Since these charges are non-operational, unusual or infrequent in nature, they are excluded accordingly.

    Balance Sheet
    (in thousands, except per share amounts) (unaudited)


    September 30, December 31,
    Assets
    2023 2022
    Current assets:
    Cash and cash equivalents
    $8,725 $14,603
    Accounts receivable, net of allowance for doubtful accounts
    of $24 at September 30, 2023 and $73 at December 31, 2022
    828 1,057
    Inventories
    5,580 4,965
    Prepaid expenses and other current assets
    550 362
    Total current assets
    15,683 20,987
    Right of use asset
    1,384 2,194
    Property and equipment, net
    528 702
    Other assets
    249 312
    Total assets
    $17,844 $24,195

    Liabilities and stockholders' (deficit) equity

    Current liabilities:
    Accounts payable
    $549 $631
    Accrued compensation
    1,947 1,401
    Accrued expenses and other current liabilities
    897 657
    Leasehold liability, current portion
    1,179 1,092
    Borrowings
    13,794 14,165
    Total current liabilities
    18,366 17,946
    Leasehold liability, long-term portion
    205 1,102
    Other long-term liabilities
    627 1,001
    Total liabilities
    19,198 20,049
    Stockholders' (deficit) equity:
    Convertible preferred stock, par value $0.001
    - -
    Common stock, par value $0.001
    1 8
    Additional paid-in capital
    414,317 406,514
    Accumulated deficit
    (415,672) (402,376)
    Total stockholders' (deficit) equity
    (1,354) 4,146
    Total liabilities and stockholders' (deficit) equity
    $17,844 $24,195

    SOURCE: Avinger, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/796857/avinger-reports-third-quarter-2023-results

    Get the next $AVGR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AVGR

    DatePrice TargetRatingAnalyst
    11/15/2021$2.50 → $2.00Buy
    Aegis Capital
    6/29/2021$2.50Buy
    B. Riley Securities
    More analyst ratings

    $AVGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avinger Reports Third Quarter 2024 Results

      Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024.Third Quarter and Recent HighlightsReported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.Implemented cost reduction program designed to streamline operating costs of the peripheral business and increase focus on coronary product development

      11/7/24 4:05:00 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger to Announce Third Quarter 2024 Results on November 7, 2024

      REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1- 973-528-0011 and use passcode 442577. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.co

      10/29/24 8:00:00 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger Releases Updated Data From IMAGE-BTK in Webinar Featuring Key Opinion Leaders in the Field of Vascular Intervention

      REDWOOD CITY, CA / ACCESSWIRE / October 24, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease hosted a physician-focused webinar entitled, "New Approaches to Treating Peripheral Artery Disease (PAD) Below-the-Knee (BTK) and Promising New BTK Data." A recording of the webinar may be accessed at https://pages.avinger.com/webinar-new-approaches-to-treating-btk-pad.The webinar featured key opinion leaders in the field of vascular intervention from different specialties and geographies as follows:Dr. Michael Lichtenberg, an angiologist and the

      10/24/24 8:00:00 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Vice President, Finance Subainati Nabeel Paul sold $699 worth of shares (1,255 units at $0.56), decreasing direct ownership by 28% to 3,296 units (SEC Form 4)

      4 - Avinger Inc (0001506928) (Issuer)

      1/24/25 9:35:20 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Soinski Jeffrey M sold $2,054 worth of shares (3,690 units at $0.56), decreasing direct ownership by 6% to 55,265 units (SEC Form 4)

      4 - Avinger Inc (0001506928) (Issuer)

      1/24/25 9:34:44 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Chief Technology Officer Patel Himanshu sold $1,233 worth of shares (2,215 units at $0.56), decreasing direct ownership by 5% to 39,062 units (SEC Form 4)

      4 - Avinger Inc (0001506928) (Issuer)

      1/24/25 9:34:02 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aegis Capital reiterated coverage on Avinger with a new price target

      Aegis Capital reiterated coverage of Avinger with a rating of Buy and set a new price target of $2.00 from $2.50 previously

      11/15/21 12:33:44 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities initiated coverage on Avinger with a new price target

      B. Riley Securities initiated coverage of Avinger with a rating of Buy and set a new price target of $2.50

      6/29/21 6:16:21 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    Financials

    Live finance-specific insights

    See more
    • Avinger Reports Third Quarter 2024 Results

      Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024.Third Quarter and Recent HighlightsReported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.Implemented cost reduction program designed to streamline operating costs of the peripheral business and increase focus on coronary product development

      11/7/24 4:05:00 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger to Announce Third Quarter 2024 Results on November 7, 2024

      REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1- 973-528-0011 and use passcode 442577. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.co

      10/29/24 8:00:00 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger to Announce Second Quarter 2024 Results on August 8, 2024

      REDWOOD CITY, CA / ACCESSWIRE / July 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the second quarter 2024 after the close of trading on Thursday, August 8, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1-848-280-6550 and use passcode Avinger. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.com.A

      7/29/24 8:45:00 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Avinger Inc.

      SCHEDULE 13G/A - Avinger Inc (0001506928) (Subject)

      2/14/25 5:07:21 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Changes in Registrant's Certifying Accountant, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Avinger Inc (0001506928) (Filer)

      2/10/25 5:01:26 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Avinger Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Avinger Inc (0001506928) (Filer)

      2/5/25 5:00:31 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Avinger Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer

      REDWOOD CITY, CA / ACCESSWIRE / August 5, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the appointment of Thomas P. Davis, MD, FACC, as Chief Medical Officer for its peripheral business. As a highly experienced interventional cardiologist and key opinion leader (KOL) in the peripheral vascular space, Dr. Davis has operated at the forefront of medical device innovation and advancing patient care in a career spanning more than three decades. Dr. Davis has pioneered the use of several cutting-edge interventional technolo

      8/5/24 8:00:00 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council

      SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

      9/7/22 8:30:00 AM ET
      $AFIB
      $AVGR
      $HYPR
      $NUVA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • Avinger Announces Annual Meeting Results

      REDWOOD CITY, CA / ACCESSWIRE / December 23, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced results of its annual meeting of stockholders (the "Annual Meeting"), concluded on December 23, 2020. At the Annual Meeting, proposals were presented to elect one director to serve until the 2023 annual meeting, to ratify the appointment of the Company's public accountant for the year ended December 31, 2020, to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock spl

      12/23/20 4:50:00 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care

    $AVGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Avinger Inc.

      SC 13G - Avinger Inc (0001506928) (Subject)

      11/14/24 3:23:30 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avinger Inc.

      SC 13G/A - Avinger Inc (0001506928) (Subject)

      11/13/24 11:13:40 AM ET
      $AVGR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Avinger Inc.

      SC 13G - Avinger Inc (0001506928) (Subject)

      6/21/24 4:45:23 PM ET
      $AVGR
      Medical/Dental Instruments
      Health Care